Pharmaceutical packaging carries a responsibility far greater than appearance alone. Beyond branding, decoration, and product identification, every printed surface on a medicine pack must support patient safety, product integrity, and regulatory compliance. In recent years, this responsibility has intensified significantly, with printing inks and coatings coming under increasing scrutiny across global markets.
The reason is simple – pharmaceutical packaging is not merely a communication medium; it is an integral part of the drug-delivery system. Any potential interaction between packaging materials and the pharmaceutical product can directly affect safety, efficacy, and shelf life. As a result, regulators, brand owners, and converters are paying much closer attention to the composition, purity, migration behavior, and manufacturing consistency of inks, primers, varnishes, and coatings used in pharma packaging.
One of the strongest drivers behind this pressure is the growing concern around migration. Even where inks and coatings are applied on the non-contact side of blister foils, labels, cartons, leaflets, or laminates, there remains a risk of set-off, diffusion, penetration, or transfer through substrates under certain storage and processing conditions. Low-molecular-weight substances, residual solvents, photoinitiators, mineral-oil fractions, heavy metals, and non-intentionally added substances are now receiving greater attention than before. Regulatory thinking has clearly moved beyond the narrow concept of direct contact and increasingly considers the total packaging environment.
Another key factor is the tightening of global chemical-compliance frameworks. Although pharmaceutical-packaging regulations differ by region and application, manufacturers are increasingly expected to align with requirements linked to US FDA, EuPIA exclusion principles, REACH, Swiss Ordinance reference lists, good manufacturing practices, heavy-metal restrictions, residual-solvent controls, and substance-specific toxicological assessments. Pharma companies are also seeking stronger declarations regarding the absence of CMR substances, nitrocellulose-related concerns, aromatic amines, phthalates, bisphenol-based chemistry, and other sensitive components.
This shift is changing the role of ink and coating manufacturers. Earlier, performance attributes such as gloss, adhesion, heat resistance, rub resistance, and printability often dominated product development. Today, these must be balanced with toxicological acceptability, raw-material traceability, purity control, and documentation readiness. A technically strong ink is no longer enough unless it is supported by a robust compliance dossier, a controlled formulation philosophy, and reproducible manufacturing discipline.
Converters and pharmaceutical customers are also becoming more demanding. They increasingly ask for compliance declarations, residual-solvent data, migration-risk assessments, heavy-metal status, allergen statements, and change-control commitments. In many cases, they also expect support in audit readiness and risk evaluation. This means that the ink and coating supplier is no longer just a material vendor, but a compliance partner.
The challenge becomes even more complex in the case of high-performance coatings used in pharmaceutical packaging, such as heat-seal coatings, release coatings, protective overprint varnishes, specialty barrier layers, and functional primers. These systems sit closer to the performance core of the pack structure and therefore demand deeper understanding of formulation chemistry, interaction with substrates such as aluminum foil, PET, paper, and PVC-free alternatives, and compatibility with downstream sealing or sterilization conditions. Any regulatory gap in such systems can create approval delays or supply-chain disruption.
At the same time, sustainability is adding another layer of pressure. The move toward recyclable, PVC-free, low-VOC, and safer-by-design packaging materials is encouraging reformulation of many traditional ink and coating systems. Future-ready solutions must combine compliance, performance, and sustainability rather than treating them as separate objectives.
In this changing environment, GLS Speciality Chemicals’ Nitrofree Pharmasure printing inks, together with compatible NC-free primers and overcoat varnishes, represent a new-generation platform designed to respond to the evolving needs of pharmaceutical packaging. These solutions are not merely alternatives to conventional systems; they are strategic enablers for the next phase of compliant packaging growth.
The message from the market is clear – the future of pharmaceutical packaging inks and coatings will be shaped not only by print performance, but by regulatory intelligence and formulation responsibility. Companies that act early, document thoroughly, and innovate responsibly will be best positioned to succeed in this new era of compliance-driven packaging.
– The authors are CEO and CTO at GLS Speciality Chemicals
